{"id":"W3048875481","doi":"10.1097/spc.0000000000000519","title":"Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Pazopanib; Axitinib; Cabozantinib; Immunotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Sunitinib; Renal cell carcinoma; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001035088,0.001017711,0.002634587,0.0003537,0.0000613167,0.00005097019,0.0001430458,0.0003874482,0.0009795858],"category_scores_gemma":[0.00003902741,0.0007584398,0.0007480999,0.0005445135,0.0001646716,0.00009885959,0.0001112439,0.001041186,0.00008618944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005638239,"about_ca_system_score_gemma":0.0006134536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003872529,"about_ca_topic_score_gemma":0.000005539364,"domain_scores_codex":[0.9966401,0.000276969,0.001114848,0.001078763,0.0004137962,0.0004754738],"domain_scores_gemma":[0.998207,0.000135792,0.0005296598,0.000447172,0.0003327405,0.0003476313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005246391,0.0002908135,0.005876489,0.03961539,0.0004153646,0.0001938631,0.002742725,4.887669e-8,0.000004772355,0.00002862988,0.001835382,0.9484719],"study_design_scores_gemma":[0.002703085,0.001206185,0.003254578,0.0299819,0.0002220566,0.00002020119,0.0002886931,7.243787e-7,0.00005440771,0.00001091248,0.9616368,0.0006204738],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009169797,0.9933994,0.00001295976,0.0001102823,0.001438139,0.002915446,0.001071515,0.00004704472,0.00008820761],"genre_scores_gemma":[0.001595753,0.9914366,0.00008158393,0.0000827891,0.001145912,0.001015303,0.004421371,0.0001271242,0.00009353648],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9598014,"threshold_uncertainty_score":0.9999337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1114292077804019,"score_gpt":0.3930083387151905,"score_spread":0.2815791309347887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}